Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27654543 | 0.77 | SMN1; SMN2 (0.45) | KDM4EHTTTP53ALDH1A1MAPT | |
| SCHEMBL11142730 | 0.76 | KMT2A (0.53) | KMT2AMEN1KDM4EHTTALDH1A1 | |
| SCHEMBL11150434 | 0.74 | CA1 (0.55) | KMT2AMEN1KDM4EHTTTSHR | |
| SCHEMBL14944050 | 0.74 | ALDH1A1 (0.44) | KMT2AMEN1KDM4EHTTTP53 | |
| SCHEMBL26459294 | 0.73 | MAPT (0.46) | KMT2AKDM4EHTTPOLBALDH1A1 | |
| SCHEMBL11397967 | 0.73 | HRH3 (0.54) | KMT2AMEN1KDM4EHTTALDH1A1 | |
| SCHEMBL3843267 | 0.73 | MEN1 (0.60) | KMT2AMEN1KDM4EHTTPOLB | |
| SCHEMBL11165443 | 0.72 | MEN1 (0.59) | KMT2AMEN1KDM4EHTTPOLB | |
| SCHEMBL20812769 | 0.72 | HTT (0.48) | KMT2AMEN1KDM4EHTTPOLB | |
| SCHEMBL4054492 | 0.72 | HTT (0.62) | KMT2AMEN1KDM4EHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102272125-B | Pyridazinone derivatives | MERCK PATENT GMBH | 2014-01-08 | — | — | CN | disclosed |
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-102272125-A | Pyridazinone derivatives | — | 2011-12-07 | — | — | CN | disclosed |
| EP-2114898-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | Amgen Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008103277-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | AMGEN INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | HGF, HGFAC, MET | KMT2A 2851/4885MEN1 358/4885KDM4E 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.